Written by the Nuvirox Research Team
Key Points
- Silicon (as choline-stabilized orthosilicic acid) failed its largest, best-designed trial: no overall symptom improvement in 211 knee osteoarthritis patients, though a subgroup effect appeared in men.
- A smaller, differently-formulated silicon dioxide trial found bigger improvements than a comparator (ASU) and placebo over three months — the two silicon trials don't agree, which itself is informative.
- Silicon's proposed role is structural: supporting collagen cross-linking and bone mineral matrix, not anti-inflammatory action.
Short answer: the evidence for silicon and joint health is genuinely mixed, with the largest trial coming up empty for the overall study population. Silicon is a legitimate structural mineral — it's involved in collagen synthesis and bone matrix formation — but “involved in structure” and “relieves knee pain when you take a capsule” are two different claims, and the trial record reflects that gap.
What is silicon supposed to do for joints?
Dietary silicon, most often studied as orthosilicic acid, has documented roles in stimulating collagen type I synthesis and supporting bone mineralization. Because cartilage and the subchondral bone beneath it both depend on collagen and mineral matrix, silicon has a plausible structural rationale distinct from anti-inflammatory ingredients like curcumin or omega-3s. The theory is that adequate silicon supports the raw materials of joint architecture rather than blocking inflammatory signaling.
What does the largest trial actually show?
The best-designed test is a 12-week, multicenter, double-blind, placebo-controlled trial of choline-stabilized orthosilicic acid (ch-OSA) in 211 patients with knee osteoarthritis (Kellgren-Lawrence grade II or III), with 166 completing the study. The primary outcome — change in WOMAC pain score — showed no significant difference between ch-OSA and placebo in the overall population. A pre-specified subgroup analysis found a symptomatic improvement in men but not in women, alongside a modest reduction in cartilage-degradation biomarkers in that subgroup (DOI: 10.1186/s12891-016-1370-7). A null overall result with a subgroup signal is exactly the kind of finding that deserves honest reporting rather than being spun as a win — subgroup effects found after the fact are hypothesis-generating, not proof.
What about the smaller, more positive trial?
A separate double-blind randomized trial in 104 knee osteoarthritis patients in Tehran compared silicon dioxide (SiO2), avocado-soybean unsaponifiables (ASU), and placebo over three months. The SiO2 group showed significantly greater reductions in WOMAC pain, stiffness, and physical function scores than both the ASU and placebo groups by the three-month mark (Davoodabadi Farahani A et al., Acta Medica Iranica, 2023;61(6):343-346). This is a different silicon formulation, a different population, and a different comparator than the ch-OSA trial — and it points a different direction. Taken together, the two best human trials of silicon for knee osteoarthritis don't agree with each other, which is itself the most honest summary of where this ingredient stands.
Study snapshot: choline-stabilized orthosilicic acid (largest trial)
| Design | 12-week, multicenter, double-blind, placebo-controlled |
| Participants | 211 randomized (166 completed), knee OA grade II–III |
| Primary outcome | WOMAC pain score change at 12 weeks |
| Result | No significant difference vs. placebo overall; improvement seen in men only (subgroup) |
What silicon won't do
Silicon is not a fast-acting pain reliever, and based on the largest trial available, it isn't reliably better than placebo across a general knee osteoarthritis population. If you have significant, worsening knee pain, swelling, or reduced range of motion, that warrants a clinical evaluation rather than betting on a mineral with inconsistent trial results. Silicon supplements are generally well tolerated, with mild GI upset being the most commonly reported issue.
Dosing and timeline
The ch-OSA trial used a standardized daily dose over 12 weeks before assessing outcomes; the SiO2 trial assessed patients at weeks 4, 8, and 12, with the largest separation from comparators appearing at the three-month mark. If you're going to trial a silicon supplement, three months is a more realistic minimum evaluation window than a few weeks, based on how these studies were designed.
Silicon joins boron as a structural mineral with a plausible-but-unsettled evidence base — see our piece on boron and joint health, and on manganese, another cartilage-cofactor mineral with similarly mixed trial support.
Why might the two trials disagree?
A few concrete differences may explain why the ch-OSA and SiO2 trials reached different conclusions. The formulations were chemically different — choline-stabilized orthosilicic acid is a liquid-stabilized, highly bioavailable form, while the SiO2 trial used silicon dioxide, a different chemical form with different absorption characteristics. The comparator groups differed too: the ch-OSA trial compared against placebo alone, while the SiO2 trial compared against both placebo and avocado-soybean unsaponifiables, and reported its SiO2 group outperforming both comparators, including placebo, which is a stronger signal than beating placebo alone if it replicates. Sample sizes were also different (211 randomized vs. 104), and the ch-OSA trial’s pre-registered primary endpoint (WOMAC pain at 12 weeks) showed no significant difference, while the SiO2 trial’s comparisons across pain, stiffness, and function all favored SiO2. Until an independent, larger trial replicates one result or the other, the honest conclusion is that silicon’s effect on knee osteoarthritis symptoms remains genuinely unresolved.
FAQ
Which silicon form is best — orthosilicic acid or silicon dioxide?
The trial evidence doesn't clearly favor one form; the two largest human trials used different formulations and got different results, so “best form” isn't something the current research can answer.
Does silicon help bone density even if joint pain results are mixed?
There's separate trial evidence (in osteopenic women) that choline-stabilized orthosilicic acid can support bone collagen formation markers, which is a different outcome than joint pain relief.
Is silicon safe to take long-term?
Available trials ran 12 weeks; longer-term human safety data specific to supplemental silicon is more limited, though no major safety signals have emerged in the trials conducted so far.
Should men and women expect different results?
The largest trial found a subgroup effect favoring men, but that finding came from a secondary analysis and hasn't been independently replicated, so it shouldn't be treated as an established sex-based difference yet.
Does cooking or food preparation affect silicon absorption?
Silicon in food (found in whole grains, leafy greens, and beer) is generally well absorbed as orthosilicic acid, though supplement forms are specifically engineered for higher bioavailability than most dietary sources.
From Nuvirox
Why we formulated Joint+ Restore
We look for joint ingredients with the most consistent trial support rather than chasing every mineral with a plausible mechanism. Joint+ Restore is currently being reformulated, so we're not listing specific ingredients or amounts here — see the current label on the product page. Backed by our 60-day money-back guarantee, long enough to actually evaluate it the way the research says you should.
Learn more about Joint+ Restore →The bottom line: silicon has a real, structural rationale for joint and bone health, but the two best human trials disagree with each other on whether it actually relieves knee osteoarthritis symptoms. That's a genuinely unsettled ingredient, not a clear win or a clear dud — and it's worth knowing that going in rather than expecting a guaranteed result.
References
- Geusens P, Pavelka K, Rovensky J, et al. A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis. BMC Musculoskelet Disord. 2017;18:2. DOI: 10.1186/s12891-016-1370-7.
- Davoodabadi Farahani A, et al. The Effect of Silicon Dioxide on Knee Osteoarthritis: A Randomized Clinical Trial. Acta Med Iran. 2023;61(6):343-346.
- Spector TD, Calomme MR, Anderson SH, et al. Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial. BMC Musculoskelet Disord. 2008;9:85. DOI: 10.1186/1471-2474-9-85.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.